These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27472952)

  • 1. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
    Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
    Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
    Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
    Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
    Prasad S; Yadav VR; Sung B; Reuter S; Kannappan R; Deorukhkar A; Diagaradjane P; Wei C; Baladandayuthapani V; Krishnan S; Guha S; Aggarwal BB
    Clin Cancer Res; 2012 Sep; 18(18):4942-53. PubMed ID: 22832932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid potentiated oxaliplatin to induce apoptosis in colorectal cancer RKO cells.
    Zheng J-; Wang SS; Shen KP; Huang XW; Li M; Chen L; Peng X; An HM; Hu B
    Pharmazie; 2020 Jun; 75(6):246-249. PubMed ID: 32539919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer.
    Wu T; Yu Y; Tu X; Ye L; Wang J; Xie C; Kuang K; Yu Y; Zhuge W; Wang Z; Cui R; Zheng Y
    J Ethnopharmacol; 2025 Jan; 336():118754. PubMed ID: 39208999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
    PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis.
    Guo LD; Shen YQ; Zhao XH; Guo LJ; Yu ZJ; Wang D; Liu LM; Liu JZ
    Phytother Res; 2015 Mar; 29(3):357-65. PubMed ID: 25418925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
    Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
    Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway.
    Wang Y; Bao X; Zhao A; Zhang J; Zhang M; Zhang Q; Ma B
    Life Sci; 2018 Aug; 207():532-549. PubMed ID: 29972765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
    Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
    Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
    Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
    Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.